Soleno Therapeutics Inc (SLNO) - News Archive

In a dramatic turn of events for Soleno Therapeutics, Inc. (NASDAQ: SLNO), investors watched their holdings plummet by nearly 28% as the company disclosed underwhelming results regarding its oral treatment for hyperphag...

Hope on the Horizon: FDA Extends Review for Diazoxide Choline in Prader-Willi Syndrome In a noteworthy development for patients and families facing Prader-Willi Syndrome (PWS), Soleno Therapeutics has announced an exten...

REDWOOD CITY, Calif., August 19, 2024 - Soleno Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases, has recently made two significant announcements....

Soleno Therapeutics Public Offering Raises Questions Amidst Financial StrugglesSoleno Therapeutics, a leading clinical-stage biopharmaceutical company focused on rare disease therapeutics, has recently undergone signifi...

Soleno Therapeutics Submits New Drug Application for DCCR Tablets to Treat Prader-Willi SyndromeThe pharmaceutical industry is constantly striving to develop innovative treatments for rare diseases, and Soleno Therapeut...

In recent developments, Soleno Therapeutics, a California-based clinical-stage biopharmaceutical company specializing in novel therapeutics for rare diseases, has announced the issuance of inducement awards to eight new...

Soleno Therapeutics Announces Proposed Public Offering of Common Stock: What it Means for InvestorsSoleno Therapeutics Inc. has recently made a significant announcement regarding its plans to offer and sell shares of it...

Prader-Willi Syndrome (PWS) is a complex genetic disorder characterized by hyperphagia (excessive appetite) and a range of behavioral issues. Soleno Therapeutics has recently published a peer-reviewed article comparing...

Soleno Therapeutics Inc (NASDAQ: SLNO), a pioneering clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, recently made a significant announcement regarding inducemen...

REDWOOD CITY, Calif., March 08, 2024 - Soleno Therapeutics, a renowned clinical-stage biopharmaceutical company specializing in developing innovative therapies for rare diseases, has recently made an important disclosur...

Soleno Therapeutics, a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for rare diseases, has recently made significant appointments to its leadership team. These strategic ad...

Soleno Therapeutics Empowers Shareholders with Inducement AwardsREDWOOD CITY, Calif., Jan. 05, 2024 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company dedicated to developing...

Soleno Therapeutics Announces Successful Pricing of Public Offering, Significantly Boosting Shareholder ValueREDWOOD CITY, Calif., Sept. 28, 2023 - Soleno Therapeutics, Inc. (Nasdaq:SLNO), a leading clinical-stage bioph...